PPARalpha-dependent activation of cell cycle control and DNA repair genes in hepatic nonparenchymal cells.

Peroxisome proliferator-activated receptor-α (PPARα) mediates the diverse biological effects of peroxisome proliferator (PP) chemicals, including fatty acid catabolism, hepatomegaly, hepatocyte proliferation, and hepatocarcinogenesis in rodents. However, transgenic mice expressing a constitutively active PPARα in hepatocytes (VP16PPARα) do not develop hepatocellular carcinomas in spite of hepatocyte proliferation and hepatomegaly; this suggests that activation of genes in nonparenchymal cells may have a critical role in PP-induced carcinogenesis. VP16PPARα mice exhibited massive peroxisome proliferation and hepatomegaly as well as increased mortality upon Wy-14,643 treatment. Several genes involved in cell cycle or DNA damage repair, such as Chek1, Prkdc, Mcm, and Rad51, were significantly induced to a similar extent between wild-type and VP16PPARα mice after Wy-14,643 administration. This induction was completely abolished in Pparα-null mice, suggesting a PPARα-dependent pathway. These data revealed a DNA damage response signaling network as an early event upon PP treatment and provide novel putative mechanisms for PP-induced hepatocellular carcinoma.

[1]  T. P. Krishnakantha,et al.  Hepatic peroxisome proliferation: induction by two novel compounds structurally unrelated to clofibrate , 1975, Science.

[2]  R. Roberts,et al.  Mouse hepatocyte response to peroxisome proliferators: dependency on hepatic nonparenchymal cells and peroxisome proliferator activated receptor α (PPARα) , 2001, Archives of Toxicology.

[3]  Christine Dreyer,et al.  Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors , 1992, Cell.

[4]  D. Green,et al.  Chk1 Suppresses a Caspase-2 Apoptotic Response to DNA Damage that Bypasses p53, Bcl-2, and Caspase-3 , 2008, Cell.

[5]  I. Rusyn,et al.  Role of peroxisome proliferator-activated receptor-α (PPARα) in bezafibrate-induced hepatocarcinogenesis and cholestasis , 2004 .

[6]  K. Morimura,et al.  Peroxisome Proliferator-Activated Receptor α Regulates a MicroRNA-Mediated Signaling Cascade Responsible for Hepatocellular Proliferation , 2007, Molecular and Cellular Biology.

[7]  C. Vaziri,et al.  The Chk1-mediated S-phase Checkpoint Targets Initiation Factor Cdc45 via a Cdc25A/Cdk2-independent Mechanism* , 2006, Journal of Biological Chemistry.

[8]  J. Peters,et al.  Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. , 1997, Carcinogenesis.

[9]  I. Rusyn,et al.  Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis. , 2005, Carcinogenesis.

[10]  M. Gossen,et al.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Peters,et al.  Alterations in skin and stratified epithelia by constitutively activated PPARalpha. , 2006, The Journal of investigative dermatology.

[12]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.

[13]  F. Gonzalez,et al.  Hepatocyte-restricted constitutive activation of PPAR alpha induces hepatoproliferation but not hepatocarcinogenesis. , 2007, Carcinogenesis.

[14]  J. Reddy,et al.  Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis. , 2000, Mutation research.

[15]  Y. Sánchez,et al.  Regulatory Interactions between the Checkpoint Kinase Chk1 and the Proteins of the DNA-dependent Protein Kinase Complex* , 2003, Journal of Biological Chemistry.

[16]  K. Mitsumori,et al.  Effect of fenofibrate on oxidative DNA damage and on gene expression related to cell proliferation and apoptosis in rats. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[17]  I. Issemann,et al.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.

[18]  T. Willson,et al.  Peroxisome proliferator activated receptor agonists. , 1997, EXS.

[19]  James E Klaunig,et al.  PPARalpha agonist-induced rodent tumors: modes of action and human relevance. , 2003, Critical reviews in toxicology.

[20]  C. Duve,et al.  A fatty acyl-CoA oxidizing system in rat liver peroxisomes; enhancement by clofibrate, a hypolipidemic drug. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[21]  T. Pineau,et al.  Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators , 1995, Molecular and cellular biology.

[22]  I. Rusyn,et al.  WY-14,643 induced cell proliferation and oxidative stress in mouse liver are independent of NADPH oxidase. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[23]  Jiri Bartek,et al.  The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair , 2005, Nature Cell Biology.

[24]  David Y. Lai,et al.  PPARα Agonist-Induced Rodent Tumors: Modes of Action and Human Relevance , 2003 .

[25]  Yun Dai,et al.  New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network , 2010, Clinical Cancer Research.

[26]  J. Reddy,et al.  Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens , 1980, Nature.